A5015052111- Cancer Treatment and Pharmacology
- Pain Mechanisms and Treatments
- Multiple Myeloma Research and Treatments
- HER2/EGFR in Cancer Research
- Botulinum Toxin and Related Neurological Disorders
- Pharmacological Effects of Natural Compounds
- Neuropeptides and Animal Physiology
Université de Limoges
2021-2024
Among the vinca-alkaloid class, vincristine is a potent chemotherapeutic agent with significant neurotoxic effects and employed to address wide spectrum of cancer types. Recently, therapeutic potential cholecystokinin type 2 receptor (CCK2R) as target for vincristine-induced peripheral neuropathy (VIPN) was demonstrated. In this study, impact preventive CCK2R blockade using netazepide (Trio Medicines Ltd., London, UK) investigated in mouse model neuropathy. Netazepide highly selective...
The occurrence of neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting effect many commonly-used anticancer agents. Polyvalent human immunoglobulins (hIg), used the treatment several neuropathies, may alleviate pain. aim this project was to investigate preventive hIg two mouse models CIPN, induced by vincristine (VCR, 100 µg/kg/d) and oxaliplatin (OXP, 6 mg/kg/3d). Human Ig were administered one day before first injection chemotherapy. onset CIPN...
Vincristine (VCR) is responsible for the onset of VCR-induced peripheral neuropathy (VIPN), associated with neuropathic pain. Several reports have strongly linked cholecystokinin type 2 receptor (CCK2R) to nociceptive modulation. Thus, our aim was evaluate effect CCK2R blockade on VIPN, as well its interaction VCR anticancer efficacy. administrated in mice 8 days (100 µg/kg/d, i.p.). Transcriptomic analysis dorsal root ganglia (DRG) performed at day 7 and control mice. Proglumide (30...